bpc-157 peptide safety FDA panel narrowly backs unapproved drugs – NBC4 Washington This one means a lot

Longevity protocols Supporting mitochondrial function and cellular repair pathways

Anti-Inflammatory and Cytoprotective Reduces systemic inflammation markers

In a 2-year trial, acute pancreatitis was reported in 8 semaglutide-treated patients (0.27 cases per 100 patient-years) and 10 placebo-treated patients (0.33 cases per 100 patient-years), both on a background of standard of care.1 In trials of patients receiving oral semaglutide, pancreatitis was reported as a serious adverse event in 6 patients (0.1 events per 100 patient-years) receiving semaglutide versus 1 in comparator-treated patients (less than 0.1 events per 100 patient-years)

B12 Self-Injection Is Easy Learning how to self administer B12 injections unlocks a new level of independence

Ceftriaxone is administered intramuscularly in the office